Mirati Therapeutics, Inc.
MRTXNext catalyst
Adagrasib
Carcinoma, Non-Small-Cell Lung
Get an email about MRTX's next catalysts
Track Mirati Therapeutics (MRTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
Adagrasib Phase 2 Est. Readout
Estimated primary completion for Adagrasib trial (NCT06248606) in Non Small Cell Lung Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Adagrasib
Carcinoma, Non-Small-Cell Lung
MRTX849
Advanced Cancer
Sitravatinib
Clear Cell Renal Cell Carcinoma
mFOLFOX6 Regimen
Advanced Colorectal Cancer
Mocetinostat
Myelodysplastic Syndrome
AZD4547
Non-Small Cell Lung Cancer
MGCD516
Liposarcoma
Adagrasib oral dose
Advanced NSCLC
AZD6738
Non-Small Cell Lung Cancer
Vistusertib
Non-Small Cell Lung Cancer
MGCD0103
Lymphocytic Leukemia, Chronic
AZD5363
Non-Small Cell Lung Cancer
MGCD265
Non-Small Cell Lung Cancer
Adagrasib oral
Advanced NSCLC
MRTX0902
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Adagrasib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
MRTX849 | Phase 3 | Advanced Cancer | - | - |
Sitravatinib | Phase 3 | Clear Cell Renal Cell Carcinoma | - | - |
mFOLFOX6 Regimen | Phase 3 | Advanced Colorectal Cancer | - | - |
Mocetinostat | Phase 2 | Myelodysplastic Syndrome | - | - |
AZD4547 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
MGCD516 | Phase 2 | Liposarcoma | - | - |
Adagrasib oral dose | Phase 2 | Advanced NSCLC | - | - |
AZD6738 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Vistusertib | Phase 2 | Non-Small Cell Lung Cancer | - | - |
MGCD0103 | Phase 2 | Lymphocytic Leukemia, Chronic | - | - |
AZD5363 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
MGCD265 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Adagrasib oral | Phase 2 | Advanced NSCLC | - | - |
MRTX0902 | Phase 2 | Solid Tumor | - | - |
Advanced NSCLC
2 drugs in this indication
Non-Small Cell Lung Cancer
1 drug in this indication
Lymphocytic Leukemia, Chronic
1 drug in this indication
Solid Tumor
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Mirati Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 15 drug candidates in Mirati Therapeutics, Inc.'s (MRTX) pipeline across Phase 3, Phase 2. Its lead program is Adagrasib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Mirati Therapeutics, Inc.'s next FDA catalyst?→
Mirati Therapeutics, Inc.'s (MRTX) next tracked catalyst is a Phase 2 readout expected February 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MRTX biotech catalysts?→
Add MRTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Mirati Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.